ERBB2 and non-small cell lung carcinoma: RTKi revolutionised the treatment of BCR-ABL1-positive chronic myeloid leukaemia, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) [14].